infohep
  • Menu
  • Search
  • Home
  • News
  • About hepatitis
  • Countries
  • About us
  • Twitter
  • Facebook
  • RSS
  • Home
  • News
  • All the news

All the news

Showing 10 of 213 articles from: Pharmaceutical industry

Get an RSS feed of these articles

  • All news
  • infohep news
  • Editors' picks from other sources
  • Major hep B players Gilead and Vir join forces to find a cure

    Fierce Biotech / 18 January 2021

  • South Africa: Breakthrough hepatitis C medicines remain in regulatory limbo

    Daily Maverick / 04 August 2020

  • Gilead axes $445M Precision Biosciences gene therapy hep B pact

    Fierce Biotech / 14 July 2020

  • 'Another swing, another miss' for Gilead as NASH combo flops in phase 2

    Fierce Biotech / 16 December 2019

  • Pharma sells states on ‘Netflix Model’ to wipe out hep c. but at what price?

    MedCity News / 27 October 2019

  • Cost of Hepatitis C Drug Skyrockets 1,422% after Patent Approval

    Folha de S.Paulo / 24 October 2019

  • Gilead’s stealing hep C share with its cut-rate Epclusa and Harvoni generics

    Fierce Pharma / 23 September 2019

  • GSK to develop Ionis hepatitis B drugs

    PM LIve / 30 August 2019

  • Louisiana is creating a drug-price revolution

    The Hill / 21 May 2019

  • Gilead gets 'gold' in England's hepatitis C eradication drive

    PMLive / 21 May 2019

← First12345...22Next →
Other pages in this section
  • Latest news
  • All the news
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C
    • Hepatitis D
    • Hepatitis E
    • Coronavirus
    • NAFLD
    • Treatment for hepatocellular carcinoma
    • Transmission, epidemiology and prevention
    • Health services, policy and advocacy
      • Access to medicines & diagnostics
      • Hepatitis C elimination
      • Models of care
      • Finance, funding & health economics
      • National policy
      • European policy
      • International policy
      • Activism and civil society
      • Pharmaceutical industry
    • Social issues
  • Conference news
  • Noticeboard
  • Email bulletins
  • News feeds

  • Contact us
  • Terms and conditions
  • Accessibility
  • Privacy and cookies

Latest hepatitis news

Sign-up for our monthly email bulletin Follow us on Twitter Find us on Facebook

The information on this website is intended to support, rather than replace, consultation with a healthcare professional.

©NAM Publications 2022. All rights reserved. We are not responsible for the content of external websites.

Company limited by guarantee. Registered in England & Wales, number: 2707596. Registered charity, number: 1011220

Infohep has been supported by a grant from Gilead Sciences Europe Ltd. Our funder has had no editorial control over the site’s content.

infohep

Latest treatment news and information for patient advocates and people working in hepatitis in Europe.

infohep is produced by NAM. Find out more about NAM

www.infohep.org/page//about-us/Find-out-about-NAM/page/2626330//